Applied sciences for Viral Vector Manufacturing

Manufacturing of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparability of Platform Applied sciences for Viral Vector Manufacturing

Modified Vaccinia Ankara (MVA) virus is a promising vector for vaccination in opposition to numerous difficult pathogens or the remedy of some kinds of cancers. As a result of this vector is unable to duplicate in human recipients, a excessive quantity of virions per dose is required for vaccination and gene remedy. Upstream course of intensification combining perfusion applied sciences, the avian suspension cell line AGE1.CR.pIX and the virus pressure MVA-CR19 is an choice to acquire very excessive MVA yields.

Right here we in contrast totally different choices for cell retention in perfusion mode utilizing typical stirred-tank bioreactors together with an alternating tangential stream filtration system, an acoustic settler and an inclined settler. The final two choices allowed steady MVA virus harvesting. Moreover, we studied hollow-fiber based mostly bioreactors and an orbital-shaken bioreactor in perfusion mode, each accessible for single-use. Productiveness for the virus pressure MVA-CR19 was in comparison with outcomes from batch and steady manufacturing reported in literature.

Our outcomes display that MVA virus is extremely steady at 37°C in cell tradition in order that cell retention gadgets are solely required to maximise cell focus however not for steady harvesting. Utilizing a stirred-tank bioreactor, a perfusion technique throughout the entire run with working quantity enlargement after virus an infection resulted within the highest yields.

General, infectious MVA virus titers of two.1-16.5 × 109 virions/mL have been achieved in these intensified processes. Taken collectively, the examine exhibits a novel perspective on high-yield MVA virus manufacturing in typical bioreactor methods linked to numerous cell retention gadgets and addresses choices for course of intensification together with absolutely single-use perfusion platforms. This text is protected by copyright. All rights reserved.

resourcerecovery
resourcerecovery

Human IGF-BP4

MBS692040-002mg 0.02mg
EUR 450

Human IGF-BP4

MBS692040-5x002mg 5x0.02mg
EUR 1725

IGF BP4 protein

30R-AI123 20 ug
EUR 312
Description: Purified recombinant Human IGF BP4 protein

IGF BP4 protein

MBS539608-002mg 0.02mg
EUR 465

IGF BP4 protein

MBS539608-5x002mg 5x0.02mg
EUR 1945

Anti-Human IGF-BP4 Antibody

101-M460 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

IGF-BP4, human recombinant

7166-10 each
EUR 301.2

IGF-BP4, human recombinant

7166-50 each
EUR 1123.2

Human IGF-BP4 Recombinant Protein

100-200 20 µg
EUR 196.35
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 26.1 kDa protein consisting of 238 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Human IGF-BP4 Recombinant Protein

100-200S 5 µg
EUR 92.4
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 26.1 kDa protein consisting of 238 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Recombinant Human IGF-BP4 Protein

PROTP22692-1 20ug
EUR 380.4
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.

Human IGF-BP4 Recombinant Protein Lyophilized

IHUIGFBP4RLY5UG each
EUR 341
Description: Human IGF-BP4 Recombinant Protein Lyophilized

Human IGF-BP4 Recombinant Protein Lyophilized

MBS8432291-INQUIRE INQUIRE Ask for price

IGF-BP4 Recombinant Protein

40-318-0005mg 0.005 mg
EUR 311.1
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

IGF-BP4 Recombinant Protein

40-318-002mg 0.02 mg
EUR 437.1
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Recombinant Human IGF BP3

HEGFP-0903 5ug Ask for price

Recombinant Human IGF BP5

HEGFP-0905 5ug Ask for price

Recombinant Human IGF BP7

HEGFP-0907 5ug Ask for price

human anti-human IGF-1 mAb(6E)

E4A09K04-6E 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human IGF-1 mAb(8D)

E4A09K04-8D 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Rabbit Anti Human RIPK1 Monoclonal Clone IGF-18

IRBAHURIPK1IGF18C100UL each
EUR 496
Description: Rabbit Anti Human RIPK1 Monoclonal Clone IGF-18

Human IGF-BP7

MBS691503-0005mg 0.005mg
EUR 300

Human IGF-BP7

MBS691503-0025mg 0.025mg
EUR 450

Human IGF-BP7

MBS691503-5x0025mg 5x0.025mg
EUR 1725

Human IGF-BP6

MBS691832-0005mg 0.005mg
EUR 300

Human IGF-BP6

MBS691832-002mg 0.02mg
EUR 450

Human IGF-BP6

MBS691832-5x002mg 5x0.02mg
EUR 1725

Human IGF-BP3

MBS692057-0005mg 0.005mg
EUR 300

Human IGF-BP3

MBS692057-0025mg 0.025mg
EUR 450

Human IGF-BP3

MBS692057-5x0025mg 5x0.025mg
EUR 1725

Human IGF-BP2

MBS692085-0005mg 0.005mg
EUR 300

Human IGF-BP2

MBS692085-002mg 0.02mg
EUR 450

Human IGF-BP2

MBS692085-5x002mg 5x0.02mg
EUR 1725

Human IGF-BP1

MBS692092-0005mg 0.005mg
EUR 300

Human IGF-BP1

MBS692092-0025mg 0.025mg
EUR 450

Human IGF-BP1

MBS692092-5x0025mg 5x0.025mg
EUR 1725

Human IGF-BP5

MBS692152-0005mg 0.005mg
EUR 300

Human IGF-BP5

MBS692152-0025mg 0.025mg
EUR 450

Human IGF-BP5

MBS692152-5x0025mg 5x0.025mg
EUR 1725

Human IGF-1

MBS691641-01mg 0.1mg
EUR 300

Human IGF-1

MBS691641-05mg 0.5mg
EUR 450

Human IGF-1

MBS691641-5x05mg 5x0.5mg
EUR 1725

Human IGF-2

MBS691655-001mg 0.01mg
EUR 300

Human IGF-2

MBS691655-005mg 0.05mg
EUR 450

Human IGF-2

MBS691655-5x005mg 5x0.05mg
EUR 1725

IGF-BP3, Human

HY-P7020 10ug
EUR 280.8

IGF-BP5, Human

HY-P7021 50ug
EUR 721.2

IGF-BP3, human

RC216-12B3 5ug
EUR 125.26

Anti-Human IGF-BP1 Antibody

101-M457 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP2 Antibody

101-M458 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP3 Antibody

101-M459 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP5 Antibody

101-M461 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP6 Antibody

101-M462 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP7 Antibody

101-M463 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP3 Antibody

102-P144 100 µg
EUR 245.7
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP5 Antibody

102-P232 100 µg
EUR 245.7
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP7 Antibody

102-P233 100 µg
EUR 245.7
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

IGF BP3 antibody

70R-IR022 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal IGF BP3 antibody

IGF BP5 antibody

70R-IR023 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal IGF BP5 antibody

IGF BP7 antibody

70R-IR024 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal IGF BP7 antibody

IGF BP7 antibody

MBS535700-005mg 0.05mg
EUR 465

IGF BP7 antibody

MBS535700-5x005mg 5x0.05mg
EUR 1945

IGF BP3 antibody

MBS535722-005mg 0.05mg
EUR 465

IGF BP3 antibody

MBS535722-5x005mg 5x0.05mg
EUR 1945

IGF BP5 antibody

MBS535907-005mg 0.05mg
EUR 465

IGF BP5 antibody

MBS535907-5x005mg 5x0.05mg
EUR 1945

IGF-1, Human

HY-P7018 10ug
EUR 129.6

IGF-2, Human

HY-P7019 100ug
EUR 432

IGF-1, human

RC216-12 1mg
EUR 451.5

IGF-1 (Human)

MBS352114-1Bottle 1Bottle
EUR 350

IGF-1 (Human)

MBS352114-5x1Bottle 5x1Bottle
EUR 1490

IGF-1 (Human)

MBS352116-01mL 0.1mL
EUR 450

IGF-1 (Human)

MBS352116-5x01mL 5x0.1mL
EUR 1950

IGF-2 (Human)

MBS352118-1Bottle 1Bottle
EUR 350

IGF-2 (Human)

MBS352118-5x1Bottle 5x1Bottle
EUR 1490

Recombinant Human LR3 IGF-I/IGF-1

PH2031-.01 10ug
EUR 208
Description: Peptides & Proteins|Recombinant Proteins

Recombinant Human LR3 IGF-I/IGF-1

PH2031-.1 10X10ug
EUR 496
Description: Peptides & Proteins|Recombinant Proteins

Anti-Human IGF-1 Antibody

101-M454 100 µg
EUR 399
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Anti-Human IGF-2 Antibody

101-M456 100 µg
EUR 399
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Anti-Human IGF-1 Antibody

102-P28 100 µg
EUR 245.7
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Anti-Human IGF-2 Antibody

102-P29 100 µg
EUR 245.7
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Antibody for Human IGF-1

SPC-699D-A565 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 565.

Antibody for Human IGF-1

SPC-699D-A633 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 633.

Antibody for Human IGF-1

SPC-699D-A655 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 655.

Antibody for Human IGF-1

SPC-699D-A680 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 680.

Antibody for Human IGF-1

SPC-699D-A700 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 700.

Antibody for Human IGF-1

SPC-699D-APCCY7 0.1mg
EUR 565.2
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to APC/Cy7.

Antibody for Human IGF-1

SPC-699D-DY350 0.1mg
EUR 496.8
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 350.

Antibody for Human IGF-1

SPC-699D-DY405 0.1mg
EUR 483.6
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 405.

Antibody for Human IGF-1

SPC-699D-DY488 0.1mg
EUR 471.6
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 488.

Mosaic Recombinant Adeno-associated Virus Vector rAAV/DJ/CAG for Focused Gene Supply to Melanoma Cells Metastasized to the Lung

Background/goal: Sufferers with metastasized melanoma have restricted remedy choices and poor analysis. Subsequently, the event of therapies requires a brand new therapeutic strategy, of which gene remedy utilizing rAAV vectors might be proposed. The goal of the examine was to look at the effectivity of the rAAV vector to transduce mouse melanoma cells each in vitro and in vivo.

Supplies and strategies: Totally different rAAV serotypes encoding GFP underneath the management of each hen beta-actin and cytomegalovirus promoters have been used within the experiments. Intranasal, intraperitoneal, intravenous and intratumoral pathways of administration of rAAV vectors have been examined utilizing quantitative-PCR and immunohistochemical staining.

Outcomes: The very best transduction effectivity in metastatic cells in vivo was noticed 7 days after intranasal administration of a 1010 gc/0.03 ml dose of rAAV/DJ-CAG.

Conclusion: Melanoma gene remedy based mostly on rAAV vectors is a attainable remedy possibility.

Vector Competence of Aedes aegypti, Aedes albopictus and Culex quinquefasciatus from Brazil and New Caledonia for Three Zika Virus Lineages

Zika virus (ZIKV) has prompted extreme epidemics in South America starting in 2015, following its unfold via the Pacific. We comparatively assessed the vector competence of ten populations of Aedes aegypti and Ae. albopictus from Brazil and two of Ae. aegypti and one in all Culex quinquefasciatus from New Caledonia to transmit three ZIKV isolates belonging to African, Asian and American lineages.

Just lately colonized mosquitoes from eight distinct websites from each international locations have been orally challenged with the identical viral load (107 TCID50/mL) and examined after 7, 14 and 21 days. Cx. quinquefasciatus was refractory to an infection with all virus strains. In distinction, though competence assorted with geographical origin, Brazilian and New Caledonian Ae. aegypti may transmit the three ZIKV lineages, with a robust benefit for the African lineage (the one one reaching saliva one-week after problem).

Brazilian Ae. albopictus populations have been much less competent than Ae. aegypti populations. Ae. albopictus usually exhibited nearly no transmission for Asian and American lineages, however was environment friendly in transmitting the African ZIKV. Viral surveillance and mosquito management measures should be strengthened to keep away from the unfold of latest ZIKV lineages and decrease the transmission of viruses at the moment circulating.

Human anti-Human IL-8 mAb
MBS8576808-01mLAF635 0.1mL(AF635)
EUR 565
human anti-human IL-8 mAb (A5)
E4A09D07-A5A 50ug
EUR 255
Description: Available in various conjugation types.
human anti-human IL-8 mAb (6G)
E4A09D07-B5G 50ug
EUR 255
Description: Available in various conjugation types.
human anti-human IL-8 mAb (AB)
E4A09D07-C8A 50ug
EUR 255
Description: Available in various conjugation types.
human anti-human IL-8 mAb(N2)
E4A09D07-N2 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody
human anti-human IL-8 mAb(N8)
E4A09D07-N8 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody
Anti-Human IL-8
GWB-BIG258 500ug Ask for price
human anti-human IL-8 mAb (1H) Humanized Antibody
MBS8574794-01mg 0.1mg
EUR 505
human anti-human IL-8 mAb (1H) Humanized Antibody
MBS8574794-5x01mg 5x0.1mg
EUR 2015
human anti-human IL-8 mAb (2H) Humanized Antibody
MBS8574795-01mg 0.1mg
EUR 505
human anti-human IL-8 mAb (2H) Humanized Antibody
MBS8574795-5x01mg 5x0.1mg
EUR 2015
Human Interleukin-8 (IL-8) Antibody
13102-05011 150 ug
EUR 175
Human IL-8
90258-A 5 µg
EUR 130
Description: Recombinant human Interleukin-8 is a disulfide-linked monomer protein consisting of 78 amino acid residues, migrates as an approximately 9 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human Interleukin-8 mature chain was expressed in E. coli.
Human IL-8
90258-B 25 µg
EUR 205
Description: Recombinant human Interleukin-8 is a disulfide-linked monomer protein consisting of 78 amino acid residues, migrates as an approximately 9 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human Interleukin-8 mature chain was expressed in E. coli.
human IL-8
M851530020 1 unit
EUR 804.84
human-anti-human-IL-8-mAb(1H)
E409C16-hA100 Inflammation-Storm-Antibodies
EUR 276.5
Description: Inflammation Storm Antibodies
human-anti-human-IL-8-mAb(2H)
E409C16-hB100 Inflammation-Storm-Antibodies
EUR 276.5
Description: Inflammation Storm Antibodies
Anti-Human IL-8 Antibody
101-M08 500 µg
EUR 246.75
Description: Il-8 or CXCL8 was originally discovered and purified as a neutrophil chemotactic and activating factor. It was also referred to as neutrophil chemotactic factor (NCF), neutrophil activating protein (NAP), monocytederived neutrophil chemotactic factor (MDNCF), T lymphocyte chemotactic factor (TCF), granulocyte chemotactic protein (GCP) and leukocyte adhesion inhibitor (LAI). Many cell types, including monocyte/macrophages, T cells, neutrophils, fibroblasts, endothelial cells, keratinocytes, hepatocytes, chondrocytes, and various tumor cell lines, can produce CXCL8 in response to a wide variety of proinflammatory stimuli such as exposure to IL-1, TNF, LPS, and viruses. CXCL8 is a member of the alpha (CXC) subfamily of chemokines, which also includes platelet factor-4, GRO, and IP10.
Anti-Human IL-8 Antibody
102-P38 100 µg
EUR 245.7
Description: Il-8 or CXCL8 was originally discovered and purified as a neutrophil chemotactic and activating factor. It was also referred to as neutrophil chemotactic factor (NCF), neutrophil activating protein (NAP), monocytederived neutrophil chemotactic factor (MDNCF), T lymphocyte chemotactic factor (TCF), granulocyte chemotactic protein (GCP) and leukocyte adhesion inhibitor (LAI). Many cell types, including monocyte/macrophages, T cells, neutrophils, fibroblasts, endothelial cells, keratinocytes, hepatocytes, chondrocytes, and various tumor cell lines, can produce CXCL8 in response to a wide variety of proinflammatory stimuli such as exposure to IL-1, TNF, LPS, and viruses. CXCL8 is a member of the alpha (CXC) subfamily of chemokines, which also includes platelet factor-4, GRO, and IP10.
Anti-Human IL-8 Antibody
GWB-817E77 1 mL Ask for price
mAb anti-Human IL-8
MBS592019-01mg 0.1mg
EUR 365
mAb anti-Human IL-8
MBS592019-05mg 0.5mg
EUR 530
mAb anti-Human IL-8
MBS592019-5x05mg 5x0.5mg
EUR 2140
mAb anti-Human IL-8
MBS592095-01mg 0.1mg
EUR 365
mAb anti-Human IL-8
MBS592095-05mg 0.5mg
EUR 530
mAb anti-Human IL-8
MBS592095-5x05mg 5x0.5mg
EUR 2140
mAb anti-Human IL-8
MBS592159-01mg 0.1mg
EUR 365
mAb anti-Human IL-8
MBS592159-05mg 0.5mg
EUR 545
mAb anti-Human IL-8
MBS592159-5x05mg 5x0.5mg
EUR 2205
mAb anti-Human IL-8
MBS592219-01mg 0.1mg
EUR 365
mAb anti-Human IL-8
MBS592219-05mg 0.5mg
EUR 545
mAb anti-Human IL-8
MBS592219-5x05mg 5x0.5mg
EUR 2205
mAb anti-Human IL-8
MBS592256-01mg 0.1mg
EUR 365
mAb anti-Human IL-8
MBS592256-05mg 0.5mg
EUR 530
mAb anti-Human IL-8
MBS592256-5x05mg 5x0.5mg
EUR 2140
Mouse Anti-Human IL-8
MBS690051-05mg 0.5mg
EUR 525
Mouse Anti-Human IL-8
MBS690051-5x05mg 5x0.5mg
EUR 2080
Anti-Human IL-8 (CXCL8)
MBS550689-01mg 0.1mg
EUR 260
Anti-Human IL-8 (CXCL8)
MBS550689-02mg 0.2mg
EUR 335
Anti-CXCL8 / IL-8 Reference Antibody (Genentech anti-IL-8)
E24CHA784 100 μg
EUR 225
Description: Available in various conjugation types.
Human IL-8 (77aa)
MBS691916-0005mg 0.005mg
EUR 300
Human IL-8 (77aa)
MBS691916-0025mg 0.025mg
EUR 450
Human IL-8 (77aa)
MBS691916-5x0025mg 5x0.025mg
EUR 1725
IL-8 (72aa), Human
MBS8575167-0005mg 0.005mg
EUR 245
IL-8 (72aa), Human
MBS8575167-5x0005mg 5x0.005mg
EUR 940
IL-8/CXCL8, Human
HY-P7224 50ug
EUR 596.4
Human CXCL8 (IL-8)
MBS444011-0005mg 0.005mg
EUR 150
Human CXCL8 (IL-8)
MBS444011-002mg 0.02mg
EUR 210
Human CXCL8 (IL-8)
MBS444011-005mg 0.05mg
EUR 325
Human CXCL8 (IL-8)
MBS444011-01mg 0.1mg
EUR 480
Human CXCL8 (IL-8)
MBS444011-1mg 1mg
EUR 1910
Human CXCL8 (IL-8)
MBS444019-0002mg 0.002mg
EUR 195
Human CXCL8 (IL-8)
MBS444019-001mg 0.01mg
EUR 530
Human CXCL8 (IL-8)
MBS444019-005mg 0.05mg
EUR 1760
Human CXCL8 (IL-8)
MBS444019-01mg 0.1mg
EUR 2890
Human IL-8 Protein
abx060803-25ug 25 ug
EUR 644.4
Human IL-8 Protein
abx060804-25ug 25 ug
EUR 644.4
Human IL-8 protein
PRP1022-100ug 100 μg
EUR 449
Description: Human IL-8 protein, expressed in E. coli
Human IL-8 protein
PRP1022-10ug 10 μg
EUR 59
Description: Human IL-8 protein, expressed in E. coli
Human IL-8 protein
PRP1022-1mg 1 mg
EUR 2609
Description: Human IL-8 protein, expressed in E. coli
Human IL-8 protein
PRP1022-50ug 50 μg
EUR 249
Description: Human IL-8 protein, expressed in E. coli
Human IL-8 Protein
E2RB20061PT 100ul
EUR 485
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody
Human IL-8 protein
MBS9719016-001mg 0.01mg
EUR 115
Human IL-8 protein
MBS9719016-005mg 0.05mg
EUR 225
Human IL-8 protein
MBS9719016-01mg 0.1mg
EUR 345
Human IL-8 protein
MBS9719016-1mg 1mg
EUR 1745
Human IL-8 protein
MBS9719016-5x1mg 5x1mg
EUR 7815
Recombinant Human IL-8 (72a.a.)(rHu IL-8/CXCL8)
701081 25ul
EUR 235
Description: Fully biologically active when compared to standard. The ED50 as determined by a chemotaxis bioassay using human CXCR2 transfected mouse BaF3 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0 × 105 IU/mg.
Recombinant Human IL-8 (77a.a.)(rHu IL-8/CXCL8)
701082 25ul
EUR 235
Description: Fully biologically active when compared to standard. The ED50 as determined by a chemotaxis bioassay using human CXCR2 transfected mouse BaF3 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0 × 105 IU/mg.
Recombinant Human IL-8 (72a.a.) (rHu IL-8/CXCL8)
MBS9419956-0025mL 0.025mL
EUR 280
Recombinant Human IL-8 (72a.a.) (rHu IL-8/CXCL8)
MBS9419956-5x0025mL 5x0.025mL
EUR 1120
Recombinant Human IL-8
6487 5 µg
EUR 194
Recombinant Human IL-8
SJB05-01 25µg/vial
EUR 342
Recombinant Human IL-8
MBS7608414-005mg 0.05mg
EUR 345
Recombinant Human IL-8
MBS7608414-02mg 0.2mg
EUR 635
Recombinant Human IL-8
MBS7608414-1mg 1mg
EUR 1800
Recombinant Human IL-8
MBS7608414-5x1mg 5x1mg
EUR 6955
Recombinant Human IL-8
MBS258218-0005mg 0.005mg
EUR 305
Recombinant Human IL-8
MBS258218-5x0005mg 5x0.005mg
EUR 1210
Interleukin-8 (IL-8) (72a.a) Human
GWB-3997EC 0.025 mg Ask for price
Anti-Human IL-8 (257) Antibody
MBS4158332-01mg 0.1mg
EUR 685
Anti-Human IL-8 (257) Antibody
MBS4158332-5x01mg 5x0.1mg
EUR 2820
Anti-Human IL-8 (807) Antibody
MBS4158333-01mg 0.1mg
EUR 685
Anti-Human IL-8 (807) Antibody
MBS4158333-5x01mg 5x0.1mg
EUR 2820
Interleukin 8, Recombinant, Human (IL-8)
MBS650704-01mg 0.1mg
EUR 475
Interleukin 8, Recombinant, Human (IL-8)
MBS650704-05mg 0.5mg
EUR 775
Interleukin 8, Recombinant, Human (IL-8)
MBS650704-5x05mg 5x0.5mg
EUR 3330
Interleukin 8, Recombinant, Human (IL-8)
MBS650074-0025mg 0.025mg
EUR 665
Interleukin 8, Recombinant, Human (IL-8)
MBS650074-5x0025mg 5x0.025mg
EUR 2845
Anti-IL-8 Antibody
A00423 1 mL
EUR 1444.8
Description: Rabbit Polyclonal IL-8 Antibody. Validated in IP, WB and tested in Human.
Anti-IL-8 Antibody
A2062-100 100 µg
EUR 472.8
Anti-IL-8 Antibody
Y123169 100 µl
EUR 320
Anti-IL-8 Antibody
ER1706-67 100ul
EUR 189
Description: Interleukin 8 (IL-8 or chemokine (C-X-C motif) ligand 8, CXCL8) is a chemokine produced by macrophages and other cell types such as epithelial cells, airway smooth muscle cells and endothelial cells. IL-8, also known as neutrophil chemotactic factor, has two primary functions. It induces chemotaxis in target cells, primarily neutrophils but also other granulocytes, causing them to migrate toward the site of infection. IL-8 also stimulates phagocytosis once they have arrived. IL-8 is also known to be a potent promoter of angiogenesis. In target cells, IL-8 induces a series of physiological responses required for migration and phagocytosis, such as increases in intracellular Ca2+, exocytosis (e.g. histamine release), and the respiratory burst. IL-8 can be secreted by any cells with toll-like receptors that are involved in the innate immune response and has been demonstrated to be a signatory chemokine of CR2+ naive T cells, also known as recent thymic emigrants. Usually, it is the macrophages that see an antigen first, and thus are the first cells to release IL-8 to recruit other cells. Both monomer and homodimer forms of IL-8 have been reported to be potent inducers of the chemokine receptors CXCR1 and CXCR2. The homodimer is more potent, but methylation of Leu25 can block the activity of homodimers.
Anti-IL-8 Antibody
ER1901-61 100ul
EUR 189
Description: IL-8, also known as neutrophil chemotactic factor, has two primary functions. It induces chemotaxis in target cells, primarily neutrophils but also other granulocytes, causing them to migrate toward the site of infection. IL-8 also stimulates phagocytosis once they have arrived. IL-8 is also known to be a potent promoter of angiogenesis. In target cells, IL-8 induces a series of physiological responses required for migration and phagocytosis, such as increases in intracellular Ca2+, exocytosis (e.g. histamine release), and the respiratory burst.IL-8 can be secreted by any cells with toll-like receptors that are involved in the innate immune response. Usually, it is the macrophages that see an antigen first, and thus are the first cells to release IL-8 to recruit other cells. Both monomer and homodimer forms of IL-8 have been reported to be potent inducers of the chemokine receptors CXCR1 and CXCR2. The homodimer is more potent, but methylation of Leu25 can block the activity of homodimers.
Anti-IL-8 Antibody
R1511-15 100ul
EUR 189
Anti-IL-8 antibody
STJ98175 100 µl
EUR 280.8
Description: Mouse monoclonal to IL-8.
Anti-IL-8 antibody
STJ97710 200 µl
EUR 236.4
Description: Mouse monoclonal to IL-8.
Anti-IL-8 antibody
STJ97717 200 µl
EUR 236.4
Description: Mouse monoclonal to IL-8.
Anti-IL-8 antibody
STJ97720 200 µl
EUR 236.4
Description: Mouse monoclonal to IL-8.
Anti-IL-8 Antibody
MBS821263-003mL 0.03mL
EUR 185
Anti-IL-8 Antibody
MBS821263-01mL 0.1mL
EUR 255
Anti-IL-8 Antibody
MBS821263-02mL 0.2mL
EUR 335
Anti-IL-8 Antibody
MBS821263-5x02mL 5x0.2mL
EUR 1420
Anti-IL-8 antibody
MBS175692-01mg 0.1mg
EUR 450
Anti-IL-8 antibody
MBS175692-5x01mg 5x0.1mg
EUR 1870
Anti-IL-8 Antibody
MBS415375-01mL 0.1mL
EUR 440
Anti-IL-8 Antibody
MBS415375-5x01mL 5x0.1mL
EUR 1720
human DIAplex Human Inflammation - IL-8, IL-17a,
M880130004 1 unit
EUR 650.27
mAb mouse anti-human IL-8
CT264 0.5 mg
EUR 312
mouse anti-human IL-8 mAb
E409C16-m100 100μL
EUR 395
Description: Available in various conjugation types.
Mouse anti-Human IL-8 mAb
MBS8576809-005mg 0.05mg
EUR 325
Mouse anti-Human IL-8 mAb
MBS8576809-01mLAF405L 0.1mL(AF405L)
EUR 565
Mouse anti-Human IL-8 mAb
MBS8576809-01mLAF405S 0.1mL(AF405S)
EUR 565
Mouse anti-Human IL-8 mAb
MBS8576809-01mLAF610 0.1mL(AF610)
EUR 565
Mouse anti-Human IL-8 mAb
MBS8576809-01mLAF635 0.1mL(AF635)
EUR 565